LRRK2/Dardarin antibody | knockout validation | Neuromab 73-253,75-253
DOI
//dx.doi.org/10.13070/ko.en.7.2243
Date
2017-04-08

This is a knockout-validated antibody summary, based on the publication "Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG2a

Company: Neuromab

Antibody: LRRK2/Dardarin

Catalog number: 73-253,75-253

Summary: Mouse monoclonal IgG2a against a fusion protein corresponding to amino acids 970-2527 (C-terminus) of human LRRK2. Epitope mapped to within amino acids 1836-1845. Reacts with human, mouse and rat. Suitable for immunoblot, immunocytochemistry, immunohistochemistry and immunoprecipitation.

Validation Method

Western blot

Sample

Kidneys from WT and and LRRK2 KO rats. Frozen tissues were lysed in radioimmunoprecipitation buffer.

Primary incubation

1:1,000 dilution.

Secondary incubation

1:3,000–1:5,000 dilution peroxidase-conjugated goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).

Detection

Enhanced chemiluminescence.

Figure

Western blot of LRRK2 in total kidney protein lysates from 12-month-old WT and LRRK2 KO rats. Please see Figure 1c in the article [1].

References
  1. Boddu R, Hull T, Bolisetty S, Hu X, Moehle M, Daher J, et al. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Hum Mol Genet. 2015;24:4078-93 pubmed publisher